KRAS and plasma cell myeloma: Interestingly, in multiple myeloma, KRAS gene mutations were frequently found in highly immunogenic tumors [74], and, in CRC patients responding to adoptive T-cell therapy, neoantigens derived from mutated KRAS (p.G12D) and presented by HLA-C*08:02 were responsible for CRC cells’ recognition and elimination [75].